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Abstract
Background: Kabuki syndrome is a rare disorder characterized by the association of mental retardation and
postnatal growth deficiency with distinctive facial appearance, skeletal anomalies, cardiac and renal malformation.
Two causative genes have been identified in patients with Kabuki syndrome. Mutation of KMT2D (MLL2) was
identified in 55–80 % of patients, while 9–14 % of KMT2D negative patients have mutation in KDM6A gene. So far,
few tumors have been reported in patients with Kabuki syndrome. We describe the first case of a patient with
spinal ependymoma and Kabuki syndrome.
Case presentation: A 23 years old girl followed at our Center for KMT2D mutated Kabuki syndrome since she was
4 years old presented with acute lumbar pain and intermittent tactile hyposthenia of the feet. Spine magnetic
resonance revealed a lumbar endocanalar mass. She underwent surgical resection of the lesion and histologic
examination showed a tanycytic ependymoma (WHO grade II).
Conclusion: Kabuki syndrome is not considered a cancer predisposition syndrome. Nonetheless, a number
of tumors have been reported in patients with Kabuki syndrome. Spinal ependymoma is a rare disease in
the pediatric and young adult population. Whereas NF2 mutations are frequently associated to ependymoma
such an association has never been described in Kabuki syndrome. To our knowledge this is the first
case of ependymoma in a KMT2D mutated Kabuki syndrome patient. Despite KMT2D role in cancer has
previously been described, no genetic data are available for previously reported Kabuki syndrome patients
with tumors. Nonetheless, the association of two rare diseases raises the suspicion for a common
determinant.
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Background
Kabuki syndrome (KS), known as Kabuki make-up
syndrome or Niikawa–Kuroki syndrome, is a rare
disorder (1:32000 live births) [1] firstly described by
Kuroki et al. in 1981 in patients that had a distinct-
ive facial appearance, skeletal anomalies, cardiac and
renal malformations, mild to moderate mental re-
tardation and postnatal growth deficiency [2]. KS is
associated with numerous alteration in body system
and apparata such as neurological abnormalities,
impairment in growth, endocrinological findings,
cardiac and otolaryngological malformations, and
other clinical manifestations [3]. Two causative
genes have been identified in KS patients. In par-
ticular, mutation in KMT2D at 12q13.12 account for
55–80 % of the patient [4], whereas 9–14 % of
KMT2D negative patients have deletions or muta-
tion in KDM6A gene at Xp11.3 [5]. The absence of
genetic mutations is not an exclusion criterion for
clinical diagnosis of KS.
Some cases in literature reported the association with
KS and cancer even if there are no conclusive findings of
the increased risk for cancer in patients with the
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syndrome and there are no data about the real incidence
of cancer in KS [3]. Notably, only scattered case reports
are found in the literature of KS associated with pre-B-
ALL, hepatoblastoma, neuroblastoma, Burkitt lymphoma
and synovial sarcoma [6–11].
Ependymoma is a tumor derived from the ependymal
cells lining the ventricular system and is the third most
common central nervous system (CNS) tumor in child-
hood. Most cases are located intracranially, in particular
in the posterior fossa; spinal location is less frequent [12].
Ependymomas are classified as subependymomas and
myxopapillary (grade I), classic (grade II), and anaplastic
(grade III), according to the World Health Organization
(WHO). In the pediatric population, half of the cases are
diagnosed in children of less than 5 years of age [13]. Most
cases of ependymoma involve adult patients, in particular
the highest rates were observed in the 45–64 years age
group. On the contrary, ependymomas are five times
more malignant in the age group < 19 years than in adults
where the incidence rate ratio (IRR) of malignant to bor-
derline malignant tumor is about 1.5. Spinal cord/cauda
equina is the primary site in 52.1 % of all cases in adults,
but in children (age < 19 years) it is involved in only about
20 % of cases [14].
We describe a KS girl with the diagnosis of grade II
ependymoma of the filum terminale.
Case presentation
A girl born at the 40th week of gestation with a weight
of 2,380 g presented hypotonia and submucous cleft
palate, surgically corrected when she was 6 years old.
Physical examination at 3 years of age showed facial
anomalies including arched eyebrows with lateral
thinning, long palpebral fissures with lateral eversion
of the lower eyelid, long eyelashes, large prominent
ears with dysplastic helices, and a depressed nasal tip,
suggestive for KS. She also had hypotonia, joint laxity,
retarded motor developmental milestones and mild
cognitive deficit. Two-dimensional color-doppler echocar-
diography and renal ultrasound examination were normal.
Genetic testing of KMT2D gene, performed by target rese-
quencing on the MiSeq (Illumina) platform showed the
heterozygosis deletion of two bases c.16085_16086delAG;
the identified variation resulted at protein level in the non-
sense mutation p.Lys5362Serfs*96.
At the age of 23, she presented with intermittent tact-
ile hypoesthesia of the feet and worsening lumbar pain.
Magnetic resonance imaging (MRI) of the spine revealed
the presence of a lumbar endocanalar mass extending
from L3 to L4, isointense on T1 and T2 weighted images
with peripheral contrast enhancement. The lesion had a
maximum cranial-caudal diameter of 45 mm with dif-
fuse compression and posterior displacement of spinal
nerve roots. At surgery, an L3 to L5 laminotomy was
performed and gross total resection of a clivable tumor
arising from the filum terminale accomplished (Fig. 1).
No neurological complications occurred. Histology revealed
a monomorphic proliferation of elongated cells with mild
nuclear atypia, surrounded by eosinophilic fibrillary stroma
with a fascicular or vaguely perivascular pattern of growth.
Cells showed diffuse positivity for glial fibrillary acidic pro-
tein (GFAP +++) and dot-like positivity for epithelial mem-
brane antigen (EMA). The mitotic index assessed by
immunohistochemical staining against anti-Ki67 was
about 3–5 % (Fig. 2). These findings led to the diag-
nosis of ependymoma, likely the tanycytic type (WHO
grade II). On the basis of site of the lesion, extent of
resection, histology and age of the patient, no other
treatment was offered after surgical resection. She re-
mains disease free fourteen months after diagnosis.
Conclusion
KS is a genetic syndrome firstly described in 1981.
Patients present with mental and postnatal growth re-
tardation associated with a characteristic facial ap-
pearance that resemble that of Kabuki Japanese
theatre. Since KS is such a rare disease, no data are
found in the literature about the incidence of cancer
and the overall survival of patients with the syn-
drome. First cases described in the literature are now
forty years old. These observations confirm that pa-
tients can survive to adulthood. The heterogeneity of
anatomical and functional defects associated with KS
can contribute in different ways to the long-term
prognosis [15]. The genetic basis of KS were identi-
fied in 2010 and firstly associated to the mutation in
KMT2D located in the chromosome 12 [4]. KMT2D
is part of the lysine methyltransferase superfamily that
are a group of evolutionarily conserved transcriptional
regulators. The role of KMT2D is the methylation of
histone 3 lysine 4 that acts as an activation mark [16,
17]. Guo et al. reported that the KMT2D deficiency
modifies cancer cell proliferation and cell migration.
Analysis of histone H3 modifications revealed that
KMT2D is essential for maintaining the level of global
H3K4 monomethylation and that its enzymatic SET
domain is directly responsible for this function. Because
they found that a majority of KMT2D binding sites were
located in regions of potential enhancer elements, they
supposed that these findings revealed the possible role of
KMT2D in tumorigenesis [16]. Kabuki syndrome muta-
tions C1430R and C1471Y reduce histone binding and
catalytic activity of KMT2D [18]. The same reduction of
function of KMT2D, due to somatic truncating mutations,
has been reported in association to childhood cases of me-
dulloblastoma and non-Hodgkin lymphoma [16].
Up to now, there are no available data regarding
KMT2D mutation status in patients with KS that
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develop cancer. One study in a large cohort of
pediatric cancer patients showed that the incidence of
monogenic syndromes was higher than expected in
the general population and that diagnoses of these
syndromes had frequently been missed. Considering
that 1 patient out of 1073 had been diagnosed with
KS [6], Bogershausen et al. reported that the hypoth-
esis of a KS predisposition to malignancies remains
questionable [3].
To our knowledge, this is the first case of spinal epen-
dymoma described in KS. Spinal ependymoma is a rare
tumor of adults that represents about 60 % of spinal
cords tumors. Pathophysiology of this tumor is not
known so far but there is a high incidence (33 %) of
spinal low grade ependymoma in patients with type 2
neurofibromatosis [19].
In conclusion, despite KS is not considered to be a
cancer predisposition syndrome, an increasing number
of tumors is being reported in these patients. No pre-
vious genetic data are available from KS patients de-
veloping tumors. KMT2D mutation is now found in
most KS cases and shows a role in cancerogenesis.
The rarity and heterogeneity of tumors descripted in
patients with KS doesn’t permit to indicate an active
oncologic surveillance in this patients. However we
think that the description of new cases and the gen-
etic characterizations of these patients can help us to
better know the role of KMT2D mutation and the
natural history of KS.
Consent
Written informed consent was obtained from the pa-
tients’ parents for publication of these Case report
and any accompanying images. A copy of the written
consent is available for review by the Editor of this
journal.
Fig. 2 Photomicrographs of ependymoma of the filum terminale. A homogeneous proliferation of oval/elongated cells embedded in eosinophilic
fibrillary stroma; a fascicular distribution and a vaguely perivascular pattern of growth are observed (a). At immunohistochemistry, a focal dot-like
positivity for epithelial membrane antigen (EMA) is evident (b). Diffuse positivity of neoplastic cells for glial fibrillary acidic protein (GFAP +++) (c)
Fig. 1 Spine MRI, sagittal pre-operative and post-operative images. Sagittal pre-operative TSE T2 WI (a) and T1 WI with Gd (b) show a lumbar
endocanalar mass extending from L3 to L4, isointense on T1 and T2 WI with peripheral contrast enhancement. Sagittal post-operative TSE T2 WI
(c) and T1 WI with Gd (d) show total resection of the tumor
Roma et al. BMC Medical Genetics  (2015) 16:80 Page 3 of 4
Abbreviations
KS: Kabuki syndrome; CNS: Central nervous system; WHO: World Health
Organization; IRR: Incidence rate ratio; MRI: Magnetic resonance imaging;
EMA: Epithelial membrane antigen.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DR has given the main contribution to conception and design of the paper;
PP, RC, FRL and MCD have been involved in drafting the manuscript; LFG
and FDC have been involved in acquisition of neuroimaging and histological
findings; RM and AC have been involved in analysis and interpretation of
data. AM, FR and CEM have been involved in revising it critically; AM has
given final approval of the version to be published. All authors read and
approved the final manuscript.
Acknowledgements
The authors would like to thank patient for collaboration.
Author details
1University Department of Pediatrics, Bambino Gesù Children’s Hospital,
IRCCS - “Tor Vergata” University, Rome, Italy. 2Department of Neuroscience
and Neurorehabilitation, Neurosurgery Unit, Bambino Gesù Children’s
Hospital, IRCCS, Rome, Italy. 3Medical Genetics Unit, Bambino Gesù Children’s
Hospital, IRCCS, Rome, Italy. 4Department of Radiology, Unit of
Neuroradiology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy.
5Department of Anatomical Pathology, Bambino Gesù Children’s Hospital,
IRCCS, Rome, Italy. 6Cytogenetics and Molecular Genetics Unit, Bambino
Gesù Children’s Hospital, IRCCS, Rome, Italy. 7Department of Hematology/
Oncology and Stem Cell Transplantation, Bambino Gesù Children’s Hospital,
IRCCS, Rome, Italy.
Received: 30 January 2015 Accepted: 28 August 2015
References
1. Niikawa N, Kuroki Y, Kajii T, Matsuura N, Ishikiriyama S, Tonoki H, et al.
Kabuki make-up (Niikawa-Kuroki) syndrome: a study of 62 patients.
Am J Med Genet. 1988;31(3):565–89.
2. Kuroki Y, Suzuki Y, Chyo H, Hata A, Matsui I. A new malformation syndrome
of long palpebral fissures, large ears, depressed nasal tip, and skeletal
anomalies associated with postnatal dwarfism and mental retardation.
J Pediatr. 1981;99:570–3.
3. Bögershausen N, Wollnik B. Unmasking Kabuki syndrome. Clin Genet.
2013;83(3):201–11.
4. Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve
HI, et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki
syndrome. Nat Genet. 2010;42(9):790–3.
5. Dentici ML, Di Pede A, Lepri FR, Gnazzo M, Lombardi MH, Auriti C, et al.
Kabuki syndrome: clinical and molecular diagnosis in the first year of life.
Arch Dis Child. 2015;100(2):158–64.
6. Merks JH, Caron HN, Hennekam RC. High incidence of malformation syndromes
in a series of 1073 children with cancer. Am J Med Genet A. 2005;134A:132–43.
7. Tumino M, Licciardello M, Sorge G, Cutrupi MC, Di Benedetto F, Amoroso L,
et al. Kabuki syndrome and cancer in two patients. Am J Med Genet A.
2010;152A:1536–9.
8. Scherer S, Theile U, Beyer V, Ferrari R, Kreck C, Rister M. Patient with Kabuki
syndrome and acute leukemia. Am J Med Genet A. 2003;122A:76–9.
9. Ijichi O, Kawakami K, Matsuda Y, Ikarimoto N, Miyata K, Takamatsu H, et al. A
case of Kabuki make-up syndrome with EBV + Burkitt’s lymphoma. Acta
Paediatr Jpn. 1996;38:66–8.
10. Shahdadpuri R, O’Meara A, O’Sullivan M, Reardon W. Low-grade fibromyxoid
sarcoma: yet another malignancy associated with Kabuki syndrome. Clin
Dysmorphol. 2008;17:199–202.
11. Casanova M, Selicorni A, Ferrari A. Cancer predisposition in children with
Kabuki syndrome. Am J Med Genet A. 2011;155A:1504.
12. Kuttesh JF, Zieber Rush S, Ater JL. Brain tumors in childhood. In: Kliegman
RM, Behrman RE, Stanton BF, St. Geme III JW, Schor NF, Behrman RE, editors.
Nelson textbook of pediatrics. 19th ed. Philadelphia, PA: Saunders Elsevier;
2011. p. 1746–53.
13. Ailon T, Dunham C, Carret AS, Tabori U, Mcneely PD, Zelcer S, et al. The role
of resection alone in select children with intracranial ependymoma: the
Canadian Pediatric Brain Tumour Consortium experience. Childs Nerv Syst.
2015;31(1):57–65.
14. Villano JL, Parker CK, Dolecek TA. Descriptive epidemiology of ependymal
tumours in the United States. Br J Cancer. 2013;108(11):2367–71.
15. Kasdon BD, Fox JE. Kabuki syndrome: diagnostic and treatment
considerations. Ment Health Fam Med. 2012;9(3):171–9.
16. Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, et al. KMT2D
maintains neoplastic cell proliferation and global histone H3 lysine 4
monomethylation. Oncotarget. 2013;4(11):2144–53.
17. Ali M, Hom RA, Blakeslee W, Ikenouye L, Kutateladze TG. Diverse functions
of PHD fingers of the MLL/KMT2 subfamily. Biochim Biophys Acta.
2014;1843(2):366–71.
18. Dhar SS, Lee SH, Kan PY, Voigt P, Ma L, Shi X, et al. Trans-tail regulation of
MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is
mediated by a tandem PHD of MLL4. Genes Dev. 2012;26:2749–62.
19. Zemmoura I, Vourc’h P, Paubel A, Ikenouye L, Kutateladze TG. A deletion
causing NF2 exon 9 skipping is associated with familial autosomal
dominant intramedullary ependymoma. Neuro Oncol. 2014;16(2):250–5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Roma et al. BMC Medical Genetics  (2015) 16:80 Page 4 of 4
